top of page
DioTree is developing first-in-class small-molecule inhibitors of DIO3, a novel therapeutic target in high-grade serous carcinoma
PUBLICATIONS
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment
Please find attached PDF full text:
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer
Please find attached PDF full text:
bottom of page